"Cytochrome P-450 CYP3A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
|Cytochrome P-450 CYP3A
- Cytochrome P-450 CYP3A
- Cytochrome P 450 CYP3A
- P-450 CYP3A, Cytochrome
- Cytochrome P-450IIIA
- Cytochrome P 450IIIA
- P-450IIIA, Cytochrome
- Erythromycin N-Demethylase
- Erythromycin N Demethylase
- N-Demethylase, Erythromycin
- Cytochrome P450 3A
- P450 3A, Cytochrome
Cytochrome P-450 CYP3A5
- Cytochrome P-450 CYP3A5
- Cytochrome P 450 CYP3A5
- P-450 CYP3A5, Cytochrome
- Cytochrome P450 3A5
- 3A5, Cytochrome P450
- P450 3A5, Cytochrome
Cytochrome P-450 CYP3A4
- Cytochrome P-450 CYP3A4
- Cytochrome P 450 CYP3A4
- P-450 CYP3A4, Cytochrome
- Cytochrome P450 3A4
- Taurochenodeoxycholate 6-alpha-Monooxygenase
- 6-alpha-Monooxygenase, Taurochenodeoxycholate
- Taurochenodeoxycholate 6 alpha Monooxygenase
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A" by people in this website by year, and whether "Cytochrome P-450 CYP3A" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A" by people in Profiles.
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation. Pharmacogenet Genomics. 2023 04 01; 33(3):59-65.
Select drug-drug interactions with colchicine and cardiovascular medications: A review. Am Heart J. 2022 10; 252:42-50.
Population pharmacokinetics of sildenafil in extremely premature infants. Br J Clin Pharmacol. 2019 12; 85(12):2824-2837.
Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018 08; 28(8):189-195.
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012 May; 91(5):881-8.
Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012 Feb; 29(1):62-7.
Biological effects of marine contaminated sediments on Sparus aurata juveniles. Aquat Toxicol. 2011 Aug; 104(3-4):308-16.
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat. 2011 May; 127(1):153-62.
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008 Jul; 84(1):111-8.
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May; 57(5):685-92.